Myclonous

Erscheinungsjahr 2026
ISBN: 978-0-443-43246-0
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 152 mm x 229 mm

Myclonous, Volume 11 in the International Review of Movement Disorders series, highlights new advances in the field, with this new volume presenting interesting chapters on topics such as Classification & Scales & Treatment, Electrophysiology, Diagnostic approach including differential diagnosis, Clinical Myclonus Syndromes, Cortical myclonus tremor, Spectrum of Progressive myclonus ataxia - Progressive myclonus epilepsy, Myclonus-dystonia, Functional myclonus, Genetic myclonus including genetic Metabolic disorders causing myclonus, Acquired myclonus (Toxic- and drug-induced, hypoxic-ischemic, Metabolic (non-genetic) and Inflammatory myclonus), Autoimmune and paraneoplastic myclonus, Neurodegenerative disorders and myclonus, and much more.

Autoren/Hrsg.

Weitere Mitwirkende

Jenner, Peter

Koning-Tijssen, Marina AJ de

Fachgebiete

• Naturwissenschaften Physik Thermodynamik Festkörperphysik, Kondensierte Materie
• Technische Wissenschaften Maschinenbau | Werkstoffkunde Technische Mechanik | Werkstoffkunde
• Technische Wissenschaften Elektronik | Nachrichtentechnik Elektronik
• Naturwissenschaften Physik Physik Allgemein

Inhaltsverzeichnis

1. Classification & Scales & Treatment
John Caviness and Ashley Pena
2. Electrophysiology
Anna Latorre and Shabbir Hussain Merchant
3. Diagnostic approach including differential diagnosis
Rodi Zutt and Martijne Oudkerk
Clinical Myclonus Syndromes
4. Cortical myclonus tremor
Antonietta Coppola, Fleur van Rootselaar and Christel Depienne
5. Spectrum of Progressive myclonus ataxia - Progressive myclonus epilepsy
Sterre van der Veen and Canafoglia Laura
6. Myclonus-dystonia
Kathryn Peall and Emmanuel Roze
7. Functional myclonus
Mark Edwards and Roberto Erro
Etiology
8. Genetic myclonus including genetic Metabolic disorders causing myclonus
Tom J. de Koning and Lisette Koens
9. Acquired myclonus (Toxic- and drug-induced, hypoxic-ischemic, Metabolic (non-genetic) and Inflammatory myclonus)
Sanjay Pandey, Jamir Pitton Rissardo and Kartika Gulati
10. Autoimmune and paraneoplastic myclonus
Jeroen Kerstens, Maarten J. Titulaer, Bart PC van de Warrenburg and Juna M. de Vries
11. Neurodegenerative disorders and myclonus
Robert Chen, Antonio Suppa, Talyta Cortez Grippe and Marco Falletti

Über Autor(innen)

Jenner, Peter
Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson's disease. He has spent the major part of his career at King's College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King's College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders.

Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson's disease patient-carer groups across the UK.